A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Abatacept (Primary)
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 18 Jan 2018 Planned End Date changed from 12 Jun 2020 to 29 Jun 2020.
- 01 Jun 2017 Planned primary completion date changed from 1 Dec 2019 to 11 Jul 2019.
- 17 Apr 2017 Planned End Date changed from 1 Apr 2019 to 1 Jun 2020.